---
title: "CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 15 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265735138.md"
datetime: "2025-11-13T13:06:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265735138.md)
  - [en](https://longbridge.com/en/news/265735138.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265735138.md)
generator: "portal-rs"
---

# CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 15 K

Revenue: As of FY2025 Q3, the actual value is USD 15 K.

EPS: As of FY2025 Q3, the actual value is USD -0.85.

EBIT: As of FY2025 Q3, the actual value is USD -5.039 M.

### Cash Flow

-   Cash and cash equivalents totaled $7.9 million as of September 30, 2025, compared to $12.2 million as of December 31, 2024. Clene expects its cash and cash equivalents, together with $1.2 million raised subsequent to September 30, 2025, will be sufficient to fund operations into the second quarter of 2026.

### Operating Expenses

-   Research and development expenses were $3.5 million for the quarter ended September 30, 2025, compared to $4.5 million for the same period in 2024. The decrease was primarily due to cost-saving initiatives and reduced manufacturing expenses.
-   General and administrative expenses were $2.2 million for the quarter ended September 30, 2025, compared to $3.4 million for the same period in 2024, mainly due to decreases in legal fees, public and investor relations expenses, and personnel expenses.

### Net Loss

-   Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter ended September 30, 2025, compared to a net loss of $8.0 million, or $1.22 per share, for the same period in 2024.

### Other Expenses

-   Total other expense was $3.1 million for the quarter ended September 30, 2025, compared to $0.2 million for the same period in 2024. The increase was primarily related to losses from changes in fair value of common stock warrant liabilities and derivative liabilities.

### Outlook / Guidance

-   Clene plans to submit a New Drug Application (NDA) in the first quarter of 2026 under an accelerated approval pathway and expects to have the first patient dosed in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 2026.

### Related Stocks

- [CLNNW.US](https://longbridge.com/en/quote/CLNNW.US.md)

## Related News & Research

- [Balanced Risk/Reward Keeps Workday at Hold as Brent Thill Raises Price Target from $205 to $225 on Potential Silver Lake Takeout Upside](https://longbridge.com/en/news/296711228.md)
- [3,759 Shares in Ferrari N.V. $RACE Acquired by X Square Capital LLC](https://longbridge.com/en/news/296700358.md)
- [Korea Investment CORP Increases Stock Position in L3Harris Technologies Inc $LHX](https://longbridge.com/en/news/296698330.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Danske Bank A S Invests $252.05 Million in Bank of America Corporation $BAC](https://longbridge.com/en/news/296695181.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**